SG11201909161PA - Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use - Google Patents
Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of useInfo
- Publication number
- SG11201909161PA SG11201909161PA SG11201909161PA SG11201909161PA SG 11201909161P A SG11201909161P A SG 11201909161PA SG 11201909161P A SG11201909161P A SG 11201909161PA SG 11201909161P A SG11201909161P A SG 11201909161PA
- Authority
- SG
- Singapore
- Prior art keywords
- dimethoxyquinolin
- fluorphenyl
- dicarboxamide
- cyclopropane
- oxy
- Prior art date
Links
- -1 6,7-dimethoxyquinolin-4-yl Chemical group 0.000 title 1
- FEHLGOYZDFFMND-UHFFFAOYSA-N cyclopropane-1,1-dicarboxamide Chemical compound NC(=O)C1(C(N)=O)CC1 FEHLGOYZDFFMND-UHFFFAOYSA-N 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511714P | 2017-05-26 | 2017-05-26 | |
| PCT/US2018/034784 WO2018218233A1 (en) | 2017-05-26 | 2018-05-26 | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909161PA true SG11201909161PA (en) | 2019-10-30 |
Family
ID=62683441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909161P SG11201909161PA (en) | 2017-05-26 | 2018-05-26 | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11279675B2 (enExample) |
| EP (1) | EP3630726B1 (enExample) |
| JP (3) | JP7166292B2 (enExample) |
| KR (1) | KR102611445B1 (enExample) |
| CN (1) | CN110621662B (enExample) |
| AU (1) | AU2018272088C1 (enExample) |
| CA (1) | CA3060370A1 (enExample) |
| DK (1) | DK3630726T3 (enExample) |
| EA (1) | EA039654B1 (enExample) |
| ES (1) | ES2909390T3 (enExample) |
| HU (1) | HUE058196T2 (enExample) |
| IL (1) | IL270780B2 (enExample) |
| MA (1) | MA48776A (enExample) |
| MX (1) | MX2019012505A (enExample) |
| PL (1) | PL3630726T3 (enExample) |
| PT (1) | PT3630726T (enExample) |
| SG (1) | SG11201909161PA (enExample) |
| UA (1) | UA127760C2 (enExample) |
| WO (1) | WO2018218233A1 (enExample) |
| ZA (1) | ZA201906127B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015218236B2 (en) * | 2014-02-14 | 2019-06-13 | Exelixis, Inc. | Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use |
| IL270780B2 (en) * | 2017-05-26 | 2025-04-01 | Exelixis Inc | Crystalline solid forms of salts of N–{4–[(7,6–dimethoxyquinolin–4–yl)oxy]phenyl}–N'–(4–fluorophenyl)cyclopropane–1,1–dicarboxamide, processes for preparation and methods of use |
| GEAP202415420A (en) | 2018-01-26 | 2024-12-25 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| CN120305263A (zh) | 2018-06-15 | 2025-07-15 | 汉达癌症医药责任有限公司 | 卡博替尼的盐类于制备治疗癌症的剂型的用途 |
| EP4631505A3 (en) * | 2018-12-13 | 2025-12-10 | Exelixis, Inc. | Crystalline forms and salt forms of a kinase inhibitor |
| SG11202111978VA (en) * | 2019-06-03 | 2021-11-29 | Exelixis Inc | Crystalline salt forms of a kinase inhibitor |
| WO2023165948A1 (en) | 2022-03-01 | 2023-09-07 | Synthon B.V. | Cabozantinib salt with l-(+)-tartaric acid and solid forms thereof |
| AU2024215796A1 (en) | 2023-01-31 | 2025-05-15 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
| US11814356B1 (en) | 2023-03-29 | 2023-11-14 | Apotex Inc. | Salt of cabozantinib |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2744997A1 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| EA038195B1 (ru) | 2009-01-16 | 2021-07-22 | Экселиксис, Инк. | Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| WO2012009722A1 (en) | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| CN103391773A (zh) | 2010-09-27 | 2013-11-13 | 埃克塞里艾克西斯公司 | 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂 |
| DK2621481T4 (da) | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
| TWI640509B (zh) | 2011-02-10 | 2018-11-11 | 艾克塞里克斯公司 | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| TWI610918B (zh) | 2011-05-02 | 2018-01-11 | 艾克塞里克斯公司 | 治療癌症及骨癌疼痛之方法 |
| GEP201606523B (en) | 2011-09-22 | 2016-08-10 | Exelixis Inc | Method for treating osteoporosis |
| WO2013066296A1 (en) | 2011-10-31 | 2013-05-10 | Hewlett-Packard Development Company, L.P. | Method of fabricating a color filter array using a multilevel structure |
| EP2776033A1 (en) | 2011-11-08 | 2014-09-17 | Exelixis, Inc. | Dual inhibitor of met and vegf for treating cancer |
| EP2775921A1 (en) | 2011-11-08 | 2014-09-17 | Exelixis, Inc. | Method of quantifying cancer treatment |
| CN104649969B (zh) | 2013-11-22 | 2019-02-12 | 广东东阳光药业有限公司 | 一种替尼类药物的盐及其制备方法 |
| AU2015218236B2 (en) * | 2014-02-14 | 2019-06-13 | Exelixis, Inc. | Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use |
| WO2015177758A1 (en) * | 2014-05-23 | 2015-11-26 | Mylan Laboratories Ltd | Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base |
| CN104961680B (zh) | 2014-11-07 | 2017-09-12 | 苏州晶云药物科技有限公司 | N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑n’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的盐酸盐及其多晶型 |
| CN104961681B (zh) | 2014-11-13 | 2017-06-13 | 苏州晶云药物科技有限公司 | 卡博替尼的粘酸盐及其晶型 |
| EP3274333B1 (en) * | 2015-03-25 | 2019-04-24 | Sandoz AG | Cabozantinib salts and their use as anti-cancer agents |
| WO2016150966A1 (en) | 2015-03-25 | 2016-09-29 | Sandoz Ag | Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride |
| US10980792B2 (en) * | 2016-09-12 | 2021-04-20 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of Cabozantinib |
| WO2018104954A1 (en) * | 2016-12-07 | 2018-06-14 | Msn Laboratories Private Limited, R&D Center | Process for the preparation of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate and its polymorphs thereof |
| IL270780B2 (en) * | 2017-05-26 | 2025-04-01 | Exelixis Inc | Crystalline solid forms of salts of N–{4–[(7,6–dimethoxyquinolin–4–yl)oxy]phenyl}–N'–(4–fluorophenyl)cyclopropane–1,1–dicarboxamide, processes for preparation and methods of use |
-
2018
- 2018-05-26 IL IL270780A patent/IL270780B2/en unknown
- 2018-05-26 WO PCT/US2018/034784 patent/WO2018218233A1/en not_active Ceased
- 2018-05-26 MA MA048776A patent/MA48776A/fr unknown
- 2018-05-26 ES ES18732548T patent/ES2909390T3/es active Active
- 2018-05-26 MX MX2019012505A patent/MX2019012505A/es unknown
- 2018-05-26 EA EA201992803A patent/EA039654B1/ru unknown
- 2018-05-26 CN CN201880027861.5A patent/CN110621662B/zh active Active
- 2018-05-26 DK DK18732548.5T patent/DK3630726T3/da active
- 2018-05-26 PL PL18732548T patent/PL3630726T3/pl unknown
- 2018-05-26 PT PT187325485T patent/PT3630726T/pt unknown
- 2018-05-26 EP EP18732548.5A patent/EP3630726B1/en active Active
- 2018-05-26 HU HUE18732548A patent/HUE058196T2/hu unknown
- 2018-05-26 AU AU2018272088A patent/AU2018272088C1/en active Active
- 2018-05-26 CA CA3060370A patent/CA3060370A1/en active Pending
- 2018-05-26 US US16/617,352 patent/US11279675B2/en active Active
- 2018-05-26 SG SG11201909161P patent/SG11201909161PA/en unknown
- 2018-05-26 KR KR1020197031409A patent/KR102611445B1/ko active Active
- 2018-05-26 UA UAA201912198A patent/UA127760C2/uk unknown
- 2018-05-26 JP JP2019562380A patent/JP7166292B2/ja active Active
-
2019
- 2019-09-17 ZA ZA2019/06127A patent/ZA201906127B/en unknown
-
2022
- 2022-02-09 US US17/668,098 patent/US11731941B2/en active Active
- 2022-08-09 JP JP2022127094A patent/JP7437460B2/ja active Active
-
2023
- 2023-06-29 US US18/344,267 patent/US12227481B2/en active Active
-
2024
- 2024-02-09 JP JP2024018527A patent/JP7659097B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3630726T (pt) | Formas sólidas cristalinas de sais de n-{4-[(6,7-dimetoxiquinolin- 4-il)oxi]fenil}-n¿-(4-fluorfenil)ciclopropano-1,1- dicarboxamida, processos para a preparação e métodos de utilização | |
| ZA201605424B (en) | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use | |
| IL283480A (en) | Solid forms of lometaferon and lometaferon salts and processes for preparing lometaferon | |
| SI3672954T1 (sl) | Spojine, njihove soli in njihova uporaba za zdravljenje bolezni | |
| MA49696A (fr) | Sel d'un composé dérivé d'aminopyridine, forme cristalline de celui-ci, et son procédé de préparation | |
| JOP20200059A1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| EP3453703A4 (en) | CRYSTALLINE FORM OF TAFAMIDIS-METHYLGLUCAMINE SALT AND MANUFACTURING METHOD AND APPLICATION THEREOF | |
| IL282006A (en) | Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | |
| IL271399A (en) | Methods for the preparation of heterocyclic 3,1-benzodioxole compounds | |
| IL241577B (en) | Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide | |
| EP3412672A4 (en) | CRYSTALLINE FORM OF A TLR7 AGONIST, METHOD OF MANUFACTURE AND USE THEREOF | |
| EP3551612A4 (en) | PROCESS FOR THE PREPARATION OF N- (4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL) -N '- (4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S) -HYDROXYBUTANYEDIOOR AND ITS POLYDROXYBUTANYMATE | |
| IL263004B (en) | A new crystalline form of n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4 -ilamino)-benzamide | |
| PL3207928T3 (pl) | Preparat złożony, zawierający nową pochodną kwasu 3-(4-(benzyloksy)fenylo)heks-4-ynowego oraz inny składnik czynny, przeznaczony do zapobiegania lub leczenia chorób metabolicznych | |
| MA44672A (fr) | Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate | |
| EP3412671A4 (en) | TLR7 AGONISTEMALEATE SALT, CRYSTALLINE FORMS C, D AND E THEREFOR, PROCESS FOR THE PREPARATION AND USE OF MALEATE SALT AND CRYSTALLINE FORMS | |
| IL289453A (en) | Process for the preparation of ridinilazole and crystalline forms thereof | |
| IL260665B (en) | Improved process for the preparation of osimertinib (azd9291) or its salt and "azd9291 aniline" or its salt | |
| IL276430A (en) | A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use | |
| HUE056419T2 (hu) | Vilanterol trifenatát amorf formája, és eljárások ennek elkészítésére | |
| ZA202200964B (en) | Salts of a compound, crystal forms of the salts and preparation method and use thereof | |
| EP3470410A4 (en) | Crystalline form of compound suppressing protein kinase activity, and application thereof | |
| IL272562B1 (en) | Compounds or pharmaceutically acceptable salts thereof for the treatment of mycobacterial infection | |
| IL290625A (en) | Crystalline forms of quinoline analogs and their salts, compositions, and methods of their use | |
| HUE047748T2 (hu) | Eljárás aminotiolészter vegyületek és sóik elõállítására |